Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A new international study led by the University of Copenhagen in Denmark has taken a significant step toward the prevention of type 1 diabetes, by showing how low doses of a cancer drug stopped it developing in disease-prone mice.
The treatment also protected the insulin-producing cells in the pancreas from being destroyed.
Dr. Dan Ploug Christensen, of the Department of Biomedical Sciences at the University of Copenhagen, and colleagues, report their findings in a recent online issue of the Proceedings of the National Academy of Sciences.
Type 1 diabetes is classed as an autoimmune disease, where for reasons that are not fully understood, the immune system attacks the insulin-producing beta cells in the islets of Langerhans in the pancreas. The body needs insulin to help regulate blood sugar.
There is currently no cure for the disease, which has to be treated with several insulin injections a day.
The incidence of type 1 diabetes varies widely among differents part of the world, but overall it is rising at around 3% a year. Scientists believe the risk of developing the disease is a combination of genes and environment.
A study presented at a conference in 2013 suggested the global rise in type 1 diabetes may be linked to reduced exposure to infectious diseases in early life.
Dr. Christensen says:
"Diabetes is a growing problem worldwide. Our research shows that very low doses of anticancer drugs used to treat lymphoma - so-called lysine deacetylase inhibitors - can reset the immune response to not attack the insulin-producing cells.
Our results are a step towards developing a preventive treatment for type 1 diabetes."
He says when they gave the drug to mice prone to develop type 1 diabetes, they found fewer immune cells in the pancreas, and more insulin was produced.
For the study the researchers used drug doses that are 100 times lower than those used in treating cancer. The lower doses have been shown to be safe in children with certain rheumatic diseases.
The drug works by blocking the molecules that send harmful inflammation signals to the insulin-producing cells in the pancreas, as Dr. Christensen explains:
"In doing so, it prevents the cells from producing a number of factors which contribute to destroying the cells when exposed to inflammation."
The researchers also showed that the cancer drug delayed the destruction of human cells in donated insulin-producing tissue that was subjected to the inflammation signals.
The next step will be to test the drug in clinical trials to see if it prevents development of type 1 diabetes in people at higher risk for the disease, for instance in those whose close relatives already have it.
Meanwhile, in June 2013, another team in the US revealed how a type 1 diabetes vaccine showed promise in a small trial.
In that study, led by Stanford University School of Medicine, researchers tested a DNA-based vaccine that switches off the part of the immune system that destroys insulin-producing pancreatic cells. The vaccine is unusual in that most vaccines are designed to boost the immune system.
Written by Catharine Paddock PhD
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection; Dan Ploug Christensen, Conny Gysemans, Morten Lundh, Mattias Salling Dahllöf, Daniel Noesgaard, Søren Fisker Schmidt, Susanne Mandrup, Nikolai Birkbak, Christopher T. Workman, Lorenzo Piemonti, Lykke Blaabjerg, Valmen Monzani, Gianluca Fossati, Paolo Mascagni, Steven Paraskevas, Reid A. Aikin, Nils Billestrup, Lars Groth Grunnet, Charles A. Dinarello, Chantal Mathieu, and Thomas Mandrup-Poulsen; PNAS online 6 January 2014; DOI: 10.1073/pnas.1320850111; Abstract.
Additional source: University of Copenhagen news release 9 January 2014.
Visit our Diabetes category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Paddock, Catharine. "Type 1 diabetes in mice averted with cancer drug." Medical News Today. MediLexicon, Intl., 13 Jan. 2014. Web.
8 Mar. 2014. <http://www.medicalnewstoday.com/articles/271038>
Paddock, C. (2014, January 13). "Type 1 diabetes in mice averted with cancer drug." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/271038.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.